Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:11 June 2012
Reviewer: Joerg F. Schlaak
Reviewer's report:
Kamimura and coworkers have conducted a phase I dose-escalating study using
transarterial chemotherapy that utilized CDDP powder (DDP-H) in combination
with miriplatin for the treatment of unresectable hepatocellular carcinoma (HCC).
In their cohort of 9 patients no dose-limiting toxicity was observed. A partial
response was obtained in 1 patient while four showed stable disease.
Several major points need to be addressed:
In the abstract a disease control rate of 40% is reported while in table 3 this
number ranged between 50% and 66%. This should be clarified.
In the patients selection criteria it is stated that “no other therapeutic treatment
was found to be effective” while the minimal interval to the previous treatment
was only 4 weeks. Apparently, 8 out of 9 patients had received CDDP therapy
before where a 4-week interval is certainly too short to convincingly assess
disease progression. Thus, the authors should state the interval to the previous
therapy for each patient and clarify the individual treatment history.
The introduction is far too lengthy and should be more focused on the literature
that is available on the subject.
In figure 2 tumor marker levels are shown for each dosing group. It would be
more informative, however, if individual levels were shown possibly arranged
according to radiological response.
The manuscript needs the thorough attention of a native speaker.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:11 June 2012
Reviewer: Joerg F. Schlaak
Reviewer's report:
Kamimura and coworkers have conducted a phase I dose-escalating study using
transarterial chemotherapy that utilized CDDP powder (DDP-H) in combination
with miriplatin for the treatment of unresectable hepatocellular carcinoma (HCC).
In their cohort of 9 patients no dose-limiting toxicity was observed. A partial
response was obtained in 1 patient while four showed stable disease.
Several major points need to be addressed:
In the abstract a disease control rate of 40% is reported while in table 3 this
number ranged between 50% and 66%. This should be clarified.
In the patients selection criteria it is stated that “no other therapeutic treatment
was found to be effective” while the minimal interval to the previous treatment
was only 4 weeks. Apparently, 8 out of 9 patients had received CDDP therapy
before where a 4-week interval is certainly too short to convincingly assess
disease progression. Thus, the authors should state the interval to the previous
therapy for each patient and clarify the individual treatment history.
The introduction is far too lengthy and should be more focused on the literature
that is available on the subject.
In figure 2 tumor marker levels are shown for each dosing group. It would be
more informative, however, if individual levels were shown possibly arranged
according to radiological response.
The manuscript needs the thorough attention of a native speaker.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:11 June 2012
Reviewer: Joerg F. Schlaak
Reviewer's report:
Kamimura and coworkers have conducted a phase I dose-escalating study using
transarterial chemotherapy that utilized CDDP powder (DDP-H) in combination
with miriplatin for the treatment of unresectable hepatocellular carcinoma (HCC).
In their cohort of 9 patients no dose-limiting toxicity was observed. A partial
response was obtained in 1 patient while four showed stable disease.
Several major points need to be addressed:
In the abstract a disease control rate of 40% is reported while in table 3 this
number ranged between 50% and 66%. This should be clarified.
In the patients selection criteria it is stated that “no other therapeutic treatment
was found to be effective” while the minimal interval to the previous treatment
was only 4 weeks. Apparently, 8 out of 9 patients had received CDDP therapy
before where a 4-week interval is certainly too short to convincingly assess
disease progression. Thus, the authors should state the interval to the previous
therapy for each patient and clarify the individual treatment history.
The introduction is far too lengthy and should be more focused on the literature
that is available on the subject.
In figure 2 tumor marker levels are shown for each dosing group. It would be
more informative, however, if individual levels were shown possibly arranged
according to radiological response.
The manuscript needs the thorough attention of a native speaker.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant